MX2022005593A - Acondicionamiento de la carga con salinidad elevada durante la cromatografia de intercambio cationico para eliminar impurezas relacionadas del producto. - Google Patents

Acondicionamiento de la carga con salinidad elevada durante la cromatografia de intercambio cationico para eliminar impurezas relacionadas del producto.

Info

Publication number
MX2022005593A
MX2022005593A MX2022005593A MX2022005593A MX2022005593A MX 2022005593 A MX2022005593 A MX 2022005593A MX 2022005593 A MX2022005593 A MX 2022005593A MX 2022005593 A MX2022005593 A MX 2022005593A MX 2022005593 A MX2022005593 A MX 2022005593A
Authority
MX
Mexico
Prior art keywords
cation exchange
exchange chromatography
product
conditioning
charge
Prior art date
Application number
MX2022005593A
Other languages
English (en)
Spanish (es)
Inventor
Natalia Gomez
Luis Diaz
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022005593A publication Critical patent/MX2022005593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2022005593A 2019-11-07 2020-11-04 Acondicionamiento de la carga con salinidad elevada durante la cromatografia de intercambio cationico para eliminar impurezas relacionadas del producto. MX2022005593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962931863P 2019-11-07 2019-11-07
PCT/US2020/058772 WO2021091932A1 (en) 2019-11-07 2020-11-04 High salt load conditioning during cation exchange chromatography to remove product-realated impurities

Publications (1)

Publication Number Publication Date
MX2022005593A true MX2022005593A (es) 2022-06-09

Family

ID=73598211

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005593A MX2022005593A (es) 2019-11-07 2020-11-04 Acondicionamiento de la carga con salinidad elevada durante la cromatografia de intercambio cationico para eliminar impurezas relacionadas del producto.

Country Status (13)

Country Link
US (1) US20220372070A1 (enExample)
EP (1) EP4055041A1 (enExample)
JP (2) JP7760500B2 (enExample)
KR (1) KR20220092969A (enExample)
CN (1) CN114746441A (enExample)
AU (1) AU2020380256A1 (enExample)
BR (1) BR112022008649A2 (enExample)
CA (1) CA3160143A1 (enExample)
CL (3) CL2022001168A1 (enExample)
IL (1) IL292594A (enExample)
MX (1) MX2022005593A (enExample)
WO (1) WO2021091932A1 (enExample)
ZA (1) ZA202205010B (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7053500A (en) * 1999-09-15 2001-04-17 Eli Lilly And Company Chymotrypsin-free trypsin
EP2001898A1 (en) 2006-03-20 2008-12-17 Medarex Inc. Protein purification
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
US9611325B2 (en) 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
CA2963692A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
JP6699085B2 (ja) * 2015-03-25 2020-05-27 東ソー株式会社 Ｆｃ結合性タンパク質の精製方法
TW202600611A (zh) 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
CN110305217B (zh) * 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用

Also Published As

Publication number Publication date
CN114746441A (zh) 2022-07-12
JP2026012744A (ja) 2026-01-27
IL292594A (en) 2022-07-01
AU2020380256A1 (en) 2022-06-09
KR20220092969A (ko) 2022-07-04
JP7760500B2 (ja) 2025-10-27
CL2025003712A1 (es) 2026-01-09
CL2022001168A1 (es) 2023-01-27
JP2022554282A (ja) 2022-12-28
EP4055041A1 (en) 2022-09-14
US20220372070A1 (en) 2022-11-24
CL2024001788A1 (es) 2024-09-27
BR112022008649A2 (pt) 2022-07-19
WO2021091932A1 (en) 2021-05-14
ZA202205010B (en) 2023-01-25
CA3160143A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
PH12021553000A1 (en) Multispecific proteins
MX2022006758A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CU20170112A7 (es) Variantes de polipeptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, así como procedimientos para la división de toxinas de fusarium
EA201891974A1 (ru) Ингибиторы связывания белка wdr5 с белками
EA202092464A1 (ru) Способы получения стабильных композиций на основе белков
MX2018001395A (es) Derivados de pirazol pirimidina y sus usos.
EA201791507A1 (ru) Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7
EA201792263A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX2017013207A (es) Inhibidores de bromodominio.
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
PH12020550099A1 (en) Fusion protein comprising an fgf-18 moiety
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
EA201691330A1 (ru) Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
CO2018010286A2 (es) Método para la purificación de proteínas
CL2022001168A1 (es) Acondicionamiento de la carga con salinidad elevada durante la cromatografía de intercambio catiónico para eliminar impurezas relacionadas del producto
EP3752901A4 (en) IDENTIFYING SUBSTITUTE 3D IMAGES FOR 2D IMAGES VIA CLASSIFICATION CRITERIA
MX2022003879A (es) Proceso para elaborar acidos alcansulfonicos.
CL2022001169A1 (es) Lavados de salinidad elevada durante cromatografía de intercambio catiónico para eliminar impurezas relacionadas con el producto
EA202190522A1 (ru) Стабилизированные тримеры гликопротеина филовируса
MX2021016092A (es) Metodos de purificacion de proteinas.
EA201990926A1 (ru) Процесс очистки fviii